PEPTIDE CORTEXThe library
← The library

GLOW

Blend (GHK-Cu + BPC-157 + TB-500)Healing/Recovery
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeRecovery / skin blend (GHK-Cu + BPC-157 + TB-500)
MechanismPre-mixed blend of GHK-Cu (Copper peptide), BPC-157 and TB-500 in one vial (commonly 70 mg). Each component is a separate research compound; the combination itself has not been studied as a product.
EffectsWhat the components are individually studied for: GHK-Cu (Copper peptide) — Skin / Hair; BPC-157 — Healing / Recovery; TB-500 — Healing / Recovery. Read each component’s own entry for its evidence.
DosingNo human dose established.
Bottom lineA vendor-defined combination: no trial has tested the blend, and its evidence is no stronger than its weakest component.
Protocols · as published1 sourced
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyOnce daily
Starting10 units once daily (about 2.33 mg blend)
EscalationNot stated
Target10 units daily. Separate-vial equivalent: BPC-157 250-500 mcg daily, TB-500 2.5-5 mg twice weekly, GHK-Cu 1-2 mg daily.
Cycle4-6 weeks on, 2-4 weeks off

Commonly 70 mg = GHK-Cu 50 + BPC-157 10 + TB-500 10. GHK-Cu is 71% of the vial by mass. No trial has tested the blend.

Batches on filenone

No tested batches on file.

Read with3
Cautions & interactions

Research-grade blend; not FDA-approved. It carries the cautions of every component — read each one’s entry. Injection-site reactions possible; discuss with a clinician, especially if on anticoagulants or immunosuppressants.

No interaction data for the blend. Each component’s interaction notes apply; avoid combining multiple research compounds without a clinician.

CV 1 of 5 — No cardiovascular outcomes data for the blend; see each component.